Aller au contenu
InsiderTrades
SIGMA
Analyse
Recommandations
TOP
Le panier
NEW
Terminal
NEW
Sociétés
Dirigeants
Screeners
Performance
Blog
FR
FR
Insiders
Trades
Sigma
Sociétés · Santé & Pharma · InsiderTrades Sigma · page 39
Secteur
3 940
Santé & Pharma
PDS Biotechnology Corp
42,5M
PERDOCEO EDUCATION Corp
2,1B
PERRIGO Co plc
1,8B
PFIZER INC
152,5B
PFP
470,5M
PHARMANUTRA
810,1M
PHARMANUTRA AVVISO DI DEPOSITO DELLA LISTA PER LA NOMINA DEL COLLEGIO SINDACALE
PHARMANUTRA CDA DELIBERA DI CONVOCARE L’ASSEMBLEA ORDINARIA E STRAORDINARIA DELLA SOCIETÀ_BOARD OF DIRECTORS CONVENE THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING
787,1M
PHARMANUTRA CS
804,3M
PHARMANUTRA CS - DEPOSITO DEL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2023
792,8M
PHARMANUTRA CS - DEPOSITO DEL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2023
804,3M
PHARMANUTRA CS - PHARMANUTRA - PHN - CETILAR AL FIANCO DI FERNANDO ALONSO
PHARMANUTRA CS PHARMANUTRA - PHN - APPROVAZIONE BILANCIO DI SOSTENIBILITA' 2022
799,5M
PHARMANUTRA CS PHARMANUTRA - PHN - APPROVAZIONE BILANCIO DI SOSTENIBILITA' 2022
787,1M
PHARMANUTRA FIRST HALF 2023 RESULTS
804,3M
PHARMANUTRA FIRST HALF 2023 RESULTS
PHARMANUTRA INTERIM MANAGMENT REPORT AS OF 30 SEPTEMBER 2023
804,3M
PHARMANUTRA INTERIM MANAGMENT REPORT AS OF 30 SEPTEMBER 2023
PHARMANUTRA NOTICE OF FILING OF THE LIST FOR THE APPOINTMENT OF THE BOARD OF STATUTORY AUDITORS
PHARMANUTRA PHARMANUTRA
PHARMANUTRA PHARMANUTRA - PHN - DEPOSITO DOCUMENTAZIONE PER ASSEMBLEA DEGLI AZIONISTI
787,1M
PHARMANUTRA PHARMANUTRA - PHN - ORIENTAMENTI DEL CDA AGLI AZIONISTI SULLA FUTURA DIMENSIONE E COMPOSIZIONE DEL NUOVO CDA - NOMINA DELL’INVESTOR RELATOR
787,1M
PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025
PHARMANUTRA PHARMANUTRA - PHN: IL CDA APPROVA IL PROGETTO DI BILANCIO DI ESERCIZIO E IL BILANCIO CONSOLIDATO AL 31 DICEMBRE 2025
799,5M
PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025
799,5M
PHARMANUTRA PHARMANUTRA - PHN: THE BOARD OF DIRECTORS APPROVED THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2025
787,1M
PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025
796,7M
PHARMANUTRA PHARMANUTRA PHN - RICAVI PRELIMINARI 2025
787,1M
PHARMANUTRA PHARMANUTRA S.P.A.: AL VIA IN MESSICO LA DISTRIBUZIONE DEI COMPLEMENTI NUTRIZIONALI A BASE DI FERRO
PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025
PHARMANUTRA PHARMANUTRA S.P.A.: CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 30 SETTEMBRE 2025
796,7M
PHARMANUTRA PHARMANUTRA S.P.A.: FIRST SIGNIFICANT SALES RESULTS IN CHINA
799,5M
PHARMANUTRA PHARMANUTRA S.P.A.: LE NOVITA SUI MERCATI ESTERI
787,1M
PHARMANUTRA PHARMANUTRA S.P.A.: NEWS AND UPDATES ON FOREIGN MARKETS
PHARMANUTRA PHARMANUTRA S.P.A.: THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
PHARMANUTRA PHARMANUTRA_PR
PHARMANUTRA PHN
PHARMANUTRA PHN - RICAVI PRELIMINARI 2023
804,3M
PHARMANUTRA PR
804,3M
PHARMANUTRA PR - PHARMANUTRA - PHN - CETILAR SIDE BY SIDE WITH FERNANDO ALONSO
787,1M
PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023
PHARMANUTRA PR - PHN PRELIMINARY REVENUES 2023
804,3M
PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT
799,5M
PHARMANUTRA PR PHARMANUTRA - PHN - THE BOARD OF DIRECTOR APPROVES THE 2022 SUSTAINABILITY REPORT
787,1M
PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023
804,3M
PHARMANUTRA RISULTATI PRIMO SEMESTRE 2023
785,2M
PHARNEXT
PHYSITRACK PLC *
132,7M
PIERREL
PIERREL
Précédent
1
...
30
...
37
38
39
40
41
...
50
60
70
...
79
Suivant